Trevena Inc. buy melinda
Start price
02.11.18
/
50%
€12.40
Target price
05.11.18
€45.10
Performance (%)
12.91%
End price
05.11.18
€14.00
Summary
This prediction ended on 05.11.18 with a price of €14.00. The prediction had a final performance of 12.91%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Trevena Inc. | -6.135% | -6.135% | -80.233% | -99.401% |
iShares Core DAX® | 2.821% | -1.953% | 15.071% | 11.862% |
iShares Nasdaq 100 | 5.285% | -5.092% | 29.254% | 40.075% |
iShares Nikkei 225® | 3.687% | -4.221% | 14.286% | 6.629% |
iShares S&P 500 | 3.577% | -2.240% | 25.546% | 38.398% |
Comments by melinda for this prediction
In the thread Trevena Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 13/11 Publication de résultats
Operates as a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics products
Trevena, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of healthcare services and development of therapies.
The company product pipeline consists of Olinvo, TRV250, and TRV734.
Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
Trevena, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of healthcare services and development of therapies.
The company product pipeline consists of Olinvo, TRV250, and TRV734.
Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
Nombre d'employés : 51 personnes.
(Vom Mitglied beendet)